butabarbital raises outcomes of ifosfamide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch. CYP3A4 inducers may perhaps enhance the metabolism of ifosfamide to its active alkylating metabolites.
butabarbital will lessen the level or outcome of oliceridine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. If coadministration using a CYP3A4 inducer is essential, contemplate expanding oliceridine dose until finally stable drug consequences are realized; keep track of for indications of opioid withdrawal.
butabarbital will decrease the extent or influence of ketoconazole by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unknown.
butabarbital will minimize the extent or impact of amlodipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
butabarbital will reduce the extent or effect of repaglinide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
Acquire this medication on an vacant tummy. Shake the oral liquid very well just before Each and every use. Evaluate the medicine using a marked measuring spoon, oral syringe, or drugs cup. The standard residence teaspoon might not keep the best quantity of liquid. Dosing
butabarbital will minimize the extent or impact of doxorubicin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
butabarbital will reduce the extent or effect of clozapine by here influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
butabarbital will lessen the extent or effect of bosentan by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Not known.
butabarbital will reduce the extent or influence of fosphenytoin by impacting hepatic enzyme CYP2C9/10 metabolism. Use Warning/Check.
butabarbital will decrease the extent or result of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
Some clients have necessary health-related therapy during the unexpected emergency Section. If angioedema involves the tongue, glottis or larynx, airway obstruction could occur and become deadly. Sufferers who create angioedema soon after treatment method with sedative-hypnotics should not be rechallenged While using the drug.
butabarbital and olopatadine intranasal each increase sedation. Stay clear of or Use Alternate Drug. Coadministration raises chance of CNS despair, which can cause additive impairment of psychomotor general performance and trigger daytime impairment.
butabarbital will decrease the extent or outcome of exemestane by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of. For clients getting exemestane that has a powerful CYP3A4 inducer the advised dose of exemestane is 50 mg daily following a food.